An international clinical trial for gantenerumab aimed at preventing inherited, early-onset Alzheimer’s disease is being launched at the Washington University School of Medicine in St. Louis. The trial, called the Primary Prevention Trial, is enrolling people with a family history of early-onset Alzheimer’s and its associated genetic mutations up to 25 years before their expected onset of dementia, starting at age 18. The study will investigate whether gantenerumab — an investigational antibody under development for Alzheimer’s…
You must be logged in to read/download the full post.
The post Clinical Trial Set for Gantenerumab in Early-onset Alzheimer’s Disease appeared first on BioNewsFeeds.